Macrogenics (MGNX) Misses Q2 EPS by 20c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Macrogenics (MGNX) Misses Q2 EPS by 20c

MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results

July 29, 2021 4:01 PM EDT

Upcoming MGC018 and margetuximab MAHOGANY clinical data presentations at European Society for Medical Oncology (ESMO) MeetingConference call scheduled for today at 4:30 p.m. ET.

ROCKVILLE, Md., July 29, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2021.

In June, we presented encouraging data from a Phase 1 study of MGC018 at ASCO. We... More